Logan Coy Related postsA Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid TumorsSeptember 11, 2026A Phase 1b/2 Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Newly Diagnosed Acute Myeloid Leukemia (AML)September 11, 2026A Phase 1b study of the pharmacokinetics, safety, and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemiaSeptember 11, 2026 Previous postA Phase 1a/1b, Open-label, Dose-escalation and Dose-expansion Study of UBX-303061 in Relapsed/Refractory B-Cell MalignanciesNext postA Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors